219 related articles for article (PubMed ID: 34030125)
1. Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib.
Florou V; Nevala-Plagemann C; Whisenant J; Maeda P; Gilcrease GW; Garrido-Laguna I
J Natl Compr Canc Netw; 2021 May; 19(5):478-482. PubMed ID: 34030125
[TBL] [Abstract][Full Text] [Related]
2. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).
Drilon A; Li G; Dogan S; Gounder M; Shen R; Arcila M; Wang L; Hyman DM; Hechtman J; Wei G; Cam NR; Christiansen J; Luo D; Maneval EC; Bauer T; Patel M; Liu SV; Ou SH; Farago A; Shaw A; Shoemaker RF; Lim J; Hornby Z; Multani P; Ladanyi M; Berger M; Katabi N; Ghossein R; Ho AL
Ann Oncol; 2016 May; 27(5):920-6. PubMed ID: 26884591
[TBL] [Abstract][Full Text] [Related]
3. Expanding the Molecular Spectrum of Secretory Carcinoma of Salivary Glands With a Novel VIM-RET Fusion.
Skálová A; Banečkova M; Thompson LDR; Ptáková N; Stevens TM; Brcic L; Hyrcza M; Michal M; Simpson RHW; Santana T; Michal M; Vaněček T; Leivo I
Am J Surg Pathol; 2020 Oct; 44(10):1295-1307. PubMed ID: 32675658
[TBL] [Abstract][Full Text] [Related]
4. A Parotid Gland Mammary Analogue Secretory Carcinoma in a 4-Year-Old Boy: Case Report and Literature Review.
Meng Z; Si W; Xiuli Z; Liu Y
Fetal Pediatr Pathol; 2023 Apr; 42(2):342-350. PubMed ID: 36053082
[No Abstract] [Full Text] [Related]
5. Clinicopathologic and molecular characterization of mammary analogue secretory carcinoma of salivary gland origin.
Baghai F; Yazdani F; Etebarian A; Garajei A; Skalova A
Pathol Res Pract; 2017 Sep; 213(9):1112-1118. PubMed ID: 28781197
[TBL] [Abstract][Full Text] [Related]
6. Mammary Analogue Secretory Carcinoma of Salivary Glands: Molecular Analysis of 25 ETV6 Gene Rearranged Tumors With Lack of Detection of Classical ETV6-NTRK3 Fusion Transcript by Standard RT-PCR: Report of 4 Cases Harboring ETV6-X Gene Fusion.
Skálová A; Vanecek T; Simpson RH; Laco J; Majewska H; Baneckova M; Steiner P; Michal M
Am J Surg Pathol; 2016 Jan; 40(1):3-13. PubMed ID: 26492182
[TBL] [Abstract][Full Text] [Related]
7. Mammary analog secretory carcinoma of the thyroid gland: A primary thyroid adenocarcinoma harboring ETV6-NTRK3 fusion.
Dogan S; Wang L; Ptashkin RN; Dawson RR; Shah JP; Sherman EJ; Michael Tuttle R; Fagin JA; Klimstra DS; Katabi N; Ghossein RA
Mod Pathol; 2016 Sep; 29(9):985-95. PubMed ID: 27282352
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic utility of phosphorylated signal transducer and activator of transcription 5 immunostaining in the diagnosis of mammary analogue secretory carcinoma of the salivary gland: A comparative study of salivary gland cancers.
Kawahara A; Taira T; Abe H; Takase Y; Kurita T; Sadashima E; Hattori S; Imamura I; Matsumoto S; Fujisaki H; Sueyoshi K; Akiba J; Kage M
Cancer Cytopathol; 2015 Oct; 123(10):603-11. PubMed ID: 26252941
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemistry with a pan-TRK antibody distinguishes secretory carcinoma of the salivary gland from acinic cell carcinoma.
Hung YP; Jo VY; Hornick JL
Histopathology; 2019 Jul; 75(1):54-62. PubMed ID: 30801752
[TBL] [Abstract][Full Text] [Related]
10. Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas.
Krings G; Joseph NM; Bean GR; Solomon D; Onodera C; Talevich E; Yeh I; Grenert JP; Hosfield E; Crawford ED; Jordan RC; van Zante A; Zaloudek C; Shin SJ; Chen YY
Mod Pathol; 2017 Aug; 30(8):1086-1099. PubMed ID: 28548128
[TBL] [Abstract][Full Text] [Related]
11. ETV6-NTRK3-positive parotid mammary analogue secretory carcinoma: a case report.
Rodríguez Cobo J; Lazuén Fernández S; Mayorga Fernández MM; Gómez Román J; Freire Salinas J; Rodríguez Duque MS; Vallejo Secadas C; Álvarez Gama J; Ibaseta Fidalgo E; Medina Del Valle J
Rom J Morphol Embryol; 2021; 62(1):309-312. PubMed ID: 34609437
[TBL] [Abstract][Full Text] [Related]
12. Novel gene fusions in secretory carcinoma of the salivary glands: enlarging the ETV6 family.
Guilmette J; Dias-Santagata D; Nosé V; Lennerz JK; Sadow PM
Hum Pathol; 2019 Jan; 83():50-58. PubMed ID: 30130630
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological investigation of secretory carcinoma cases including a successful treatment outcome using entrectinib for high-grade transformation: a case report.
Suzuki K; Harada H; Takeda M; Ohe C; Uemura Y; Kawahara A; Sawada S; Kanda A; Sengupta B; Iwai H
BMC Med Genomics; 2022 Jan; 15(1):6. PubMed ID: 34991563
[TBL] [Abstract][Full Text] [Related]
14. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Drilon A; Siena S; Ou SI; Patel M; Ahn MJ; Lee J; Bauer TM; Farago AF; Wheler JJ; Liu SV; Doebele R; Giannetta L; Cerea G; Marrapese G; Schirru M; Amatu A; Bencardino K; Palmeri L; Sartore-Bianchi A; Vanzulli A; Cresta S; Damian S; Duca M; Ardini E; Li G; Christiansen J; Kowalski K; Johnson AD; Patel R; Luo D; Chow-Maneval E; Hornby Z; Multani PS; Shaw AT; De Braud FG
Cancer Discov; 2017 Apr; 7(4):400-409. PubMed ID: 28183697
[TBL] [Abstract][Full Text] [Related]
15. Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in
Smith KM; Fagan PC; Pomari E; Germano G; Frasson C; Walsh C; Silverman I; Bonvini P; Li G
Mol Cancer Ther; 2018 Feb; 17(2):455-463. PubMed ID: 29237803
[TBL] [Abstract][Full Text] [Related]
16. Salivary Gland Secretory Carcinoma With High-Grade Transformation, CDKN2A/B Loss, Distant Metastasis, and Lack of Sustained Response to Crizotinib.
Cipriani NA; Blair EA; Finkle J; Kraninger JL; Straus CM; Villaflor VM; Ginat DT
Int J Surg Pathol; 2017 Oct; 25(7):613-618. PubMed ID: 28497708
[TBL] [Abstract][Full Text] [Related]
17. Mammary Analogue Secretory Carcinoma.
Parekh V; Stevens TM
Arch Pathol Lab Med; 2016 Sep; 140(9):997-1001. PubMed ID: 27575269
[TBL] [Abstract][Full Text] [Related]
18. TRK inhibitors in TRK fusion-positive cancers.
Drilon A
Ann Oncol; 2019 Nov; 30(Suppl_8):viii23-viii30. PubMed ID: 31738426
[TBL] [Abstract][Full Text] [Related]
19. Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report.
Kubota Y; Kawano M; Iwasaki T; Itonaga I; Tsumura H; Kaku N; Tanaka K
Medicine (Baltimore); 2023 Dec; 102(49):e36232. PubMed ID: 38065851
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic and Molecular Characterization of Four Cases of Pediatric Salivary Secretory Carcinoma (SSC), One with ETV6-RET Fusion.
Salgado CM; Alaggio R; Reyes-Múgica M; Zin A; de Vito R
Head Neck Pathol; 2021 Sep; 15(3):796-802. PubMed ID: 33459993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
